检索结果-南通市图书馆

Systematic review of atorvastatin for the treatment of Alzheimer's disease

Neural Regeneration Research 2012年第17期7卷 1344-1351页

作者： Yuan Sun Genfa Wang Zhihong Pan Shuyan Chen Department of Gerontology Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200092 China

OBJECTIVE： To assess the clinical efficacy and safety of atorvastatin in the treatment of Alzheimer＇s disease. DATA SOURCES： Medline （1948/2011-04）, Embase （1966/2011-04）, Cochrane Library （Issue 3, 2011）, Chinese National Knowledge Infrastructure （1989/2011-04）, and the Chinese Biomedical Literature Database （1979/2011-04） were searched for randomized clinical trials regardless of language. Abstracts of conference papers were manually searched. Furthermore, Current Controlled Trials （http：//***）, Clinical *** （http：//***）, and Chinese Clinical Trial Registry （http：//***） were also searched. Key words included AIzheimer disease, dementia, cognition, affection, memory dysfunction, hydroxymethylglutaryI-CoA reductase inhibitors, atorvastatin and statins. DATA SELECTION： Randomized controlled trials of grade A or B according to quality evaluation criteria of the Cochrane Collaboration were selected, in which atorvastatin and placebo were used to evaluate the effects of atorvastatin in the treatment of Alzheimer＇s disease. Study methodological quality was evaluated based on criteria described in Cochrane Reviewer＇s Handbook 5.0.1. Revman 5.1 software was used for data analysis. MAIN OUTCOME MEASURES： Clinical efficacy, safety, withdrawal from the studies, and withdrawal due to adverse effects. RESULTS： Two randomized controlled trials were included, one was scale A, and the other was scale B. All patients （n = 710, age range 50-90 years） were diagnosed as probable or possible mild to moderate Alzheimer＇s disease according to standard criteria and treated with atorvastatin 80 mg/d or placebo. There was no difference between the two groups in the final follow-up for Clinical Global Impression of Change scale （WMD = 0.13, 95%CI： 0.15 to 0.40）, the Alzheimer＇s Disease Assessment Scale-cognitive subscale （WMD = 1.05, 95%C1：-3.06 to 6.05）, Mini-Mental State Examination Scale （WMD = 0.77, 95%CI： 0.57 to 2.10）, and the Neuropsy

关键词： Alzheimer's disease dementia atorvastin diphosphonate systematic review neural regeneration

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：